SGMT

Sagimet Biosciences Inc. - Series A

4.15 USD
+0.01 (+0.24%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Sagimet Biosciences Inc. - Series A stock is down -12.63% since 30 days ago. The next earnings date is Aug 19, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 0% of the previous 1 June’s closed higher than May. 100% of analysts rate it a buy.

About Sagimet Biosciences Inc. - Series A

We are a clinical-stage biopharmaceutical company developing novel therapeutics called fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. We were incorporated in Delaware in December 2006 under the name 3-V Biosciences, Inc., and changed our name to Sagimet Biosciences Inc. in August 2019. Our principal executive offices are located at 155 Bovet Road, Suite 303, San Mateo, California.

  • JP Morgan
    Fri Jun 7, 13:22
    buy
    confirm
  • HC Wainwright & Co.
    Fri Jun 7, 11:00
    buy
    confirm
  • JP Morgan
    Fri May 24, 11:51
    buy
    confirm
  • HC Wainwright & Co.
    Fri May 24, 06:33
    buy
    confirm
  • Goldman Sachs
    Thu May 16, 07:45
    buy
    confirm
  • HC Wainwright & Co.
    Thu May 16, 06:30
    buy
    confirm